Table 5.
Potential in vitro tests of synthetic drugs for SARS-nCoV.
| Drug name | EC50/IC50 (μg/ml) | CC50(μg/ml) | SI | References |
|---|---|---|---|---|
| Nelfinavir | 0.032 ± 0.016 | 9.63 ± 1.83 | 302.1 | Yamamoto et al., 2004 |
| Remdesivir | 0.042 | >6 | >140 | Sheahan et al., 2017 |
| Chloroquine | 1.27 ± 0.17 | 37.67 ± 2.09 | 30 | Keyaerts et al., 2004 |
| Lopinavir | 4 | 32 | 8 | Chen et al., 2004 |
| Favipiravir* | 4.9 ± 2.8 | >160 | >32 | Scharton et al., 2014 |
| Abidol hydrochloride* | 8.17 ± 2.14 | 89.72 | 11.0 | Haviernik et al., 2018 |
| Ribavirin | 12.5~200 | >1000 | 5~>80 | Cinatl et al., 2003 Chen et al., 2004 |
*As no data for coronavirus available, the data here for Favipiravir is against Rift Valley fever virus (RVFV) and the data for Abidol hydrochloride is an average of the results for five strains of Zika virus (ZIKV), West Nile virus (WNV), and tick-borne encephalitis virus (TBEV).